Rosuvastatin is a new, synthetic, orally active statin, with marked low-density lipoprotein
(LDL) cholesterol-lowering activity. We conducted 2 dose-ranging studies. In the first study …

The lipid-lowering effects of rosuvastatin and atorvastatin were determined across their dose
ranges in a 6-week, randomized, double-blind trial. Three hundred seventy-four …

A total of 5 randomized, double-blind trials in patients with hypercholesterolemia were
prospectively designed to allow pooling of plasma lipid data after 12 weeks of treatment. The …

Background Despite the demonstrated benefits of low-density lipoprotein cholesterol (LDL-
C) reduction in reducing the risk of coronary heart disease, many patients receiving lipid …

Objective The primary objective of this trial was to compare the efficacy of rosuvastatin with
that of pravastatin and simvastatin for lowering low-density lipoprotein cholesterol (LDL-C) …

BACKGROUND: This double-blind, multicenter, randomized trial compared rosuvastatin and
atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with …

Rosuvastatin is a novel statin that has been shown to produce large dose-dependent
reductions in low-density lipoprotein cholesterol (LDL-C) in Western hypercholesterolemic …

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter
trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose …

This randomized, double-blind, placebo-controlled trial was conducted in 52 centers in
North America to compare the effects of the new, highly effective statin, rosuvastatin, with …

BACKGROUND:: Rosuvastatin is a new statin indicated to reduce elevated levels of total
cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase …